
|Articles|November 19, 2012
Sanofi lowers price of Zaltrap after Sloan-Kettering refusal to use it
Sanofi is lowering the price of ziv-aflibercept (Zaltrap) for previously treated colorectal cancer by half after physicians at Memorial Sloan Kettering Cancer Center (MSKCC) said that they would not use the drug, according to The New York Times.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
2
Executive Order Calls for Realignment of Childhood Vaccines
3
Q&A: Pharmacists Can Address ADA Standards Across All Settings
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































